TFPB vs QLB III in Infra-umbilical Pediatric Surgeries
Launched by NAMIK KEMAL UNIVERSITY · Dec 31, 2022
Trial Information
Current as of July 22, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is comparing two methods of regional anesthesia called Transversalis Fascial Plane (TFP) block and Quadratus Lumborum (QL) block in children undergoing lower abdominal surgeries. The goal is to see which method provides better pain relief after surgery, helping kids recover faster and reducing the need for strong pain medications. Both techniques are used to numb the area around the surgery site, potentially leading to fewer side effects than traditional pain control methods like opioids.
To participate in the study, children must be between 3 and 7 years old and have a parent or guardian who agrees to let them join. They will also need to be scheduled for elective surgery in the lower abdomen and be in generally good health. Participants can expect to receive one of the two anesthesia techniques during their surgery, and their recovery will be monitored to see how well they manage pain afterward. It's important for parents to know that this study aims to improve pain management in young patients, making surgeries safer and more comfortable.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Parental acceptation to participate and signed written consent
- • Aged between 3 and 7
- • American Society of Anesthesiologists (ASA) physical score I or II
- • Elective infra umbilical surgery
- Exclusion Criteria:
- • Parental refusal to participate
- • Known allergy to local anesthetics
- • American Society of Anesthesiologists (ASA) physical score ≥ III
- • Coagulopathy
- • Hypersensitivity history to the agents to be used
- • Local infections
- • Known anatomically or systemic disorder
- • Known growth and developmental retardation
About Namik Kemal University
Namik Kemal University is a leading academic institution dedicated to advancing research and education in the health sciences. With a commitment to innovation and excellence, the university actively sponsors clinical trials aimed at enhancing patient care and developing new therapeutic approaches. Leveraging its state-of-the-art facilities and a team of experienced researchers, Namik Kemal University fosters collaborative partnerships that drive scientific discovery and contribute to the body of knowledge in clinical medicine. Through its rigorous research programs, the university aims to improve health outcomes and address pressing medical challenges, making a significant impact on both local and global health communities.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Tekirdağ, , Turkey
Patients applied
Trial Officials
Onur Baran, Asst. Prof.
Study Chair
Namik Kemal University
Ayhan Şahin, Asst. Prof.
Principal Investigator
Namik Kemal University
Cavidan Arar, Prof.
Study Director
Namik Kemal University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials